Joining the Emmes Family
As of the 11th of May 2021, Orphan Reach were acquired by Emmes, a global, full-service CRO dedicated to supporting the advancement of public health and biopharmaceutical innovation.
Founded in 1977, Emmes has conducted over 2000 clinical studies across a broad range of therapeutic areas, with significant expertise in infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders and maternal and child health. Emmes has a long history supporting research in cell and gene therapies as well as rare diseases across a wide range of therapeutic areas. Expertise in bioinformatics and adaptive/alternative study designs has enabled Emmes’ clients to conduct especially challenging rare disease studies.
Orphan Reach and Emmes share a passion for research, a dedication to the patients in our trials and successful, long-term collaborations with our clients. This merger is a positive step for Orphan Reach and the next chapter in our history, that will further extend our leadership in rare and orphan disease research and ultimately lead to new treatment options for patients.
Combining Emmes’ strategic drug development and advanced statistical capabilities with the exceptional patient-centred global operational experience of Orphan Reach will significantly benefit our biopharmaceutical customers who are in need of pragmatic solutions for their rare disease drug development programmes.
For any queries regarding the Orphan Reach-Emmes merger, please email: info@orphan-reach.com
